The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Utility of Combinations of Biomarkers, Cognitive Markers, and Risk Factors to Predict Conversion From Mild Cognitive Impairment to Alzheimer Disease in Patients in the Alzheimer's Disease Neuroimaging Initiative
Abstract
CONTEXT: Biomarkers have become increasingly important in understanding neurodegenerative processes associated with Alzheimer disease. Markers include regional brain volumes, cerebrospinal fluid measures of pathological Aβ1-42 and total tau, cognitive measures, and individual risk factors. OBJECTIVE: To determine the discriminative utility of different classes of biomarkers and cognitive markers by examining their ability to predict a change in diagnostic status from mild cognitive impairment to Alzheimer disease. DESIGN: Longitudinal study. PARTICIPANTS: We analyzed the Alzheimer's Disease Neuroimaging Initiative database to study patients with mild cognitive impairment who converted to Alzheimer disease (n = 116) and those who did not convert (n = 204) within a 2-year period. We determined the predictive utility of 25 variables from all classes of markers, biomarkers, and risk factors in a series of logistic regression models and effect size analyses. SETTING: The Alzheimer's Disease Neuroimaging Initiative public database. OUTCOME MEASURES: Primary outcome measures were odds ratios, pseudo- R(2)s, and effect sizes. RESULTS: In comprehensive stepwise logistic regression models that thus included variables from all classes of markers, the following baseline variables predicted conversion within a 2-year period: 2 measures of delayed verbal memory and middle temporal lobe cortical thickness. In an effect size analysis that examined rates of decline, change scores for biomarkers were modest for 2 years, but a change in an everyday functional activities measure (Functional Assessment Questionnaire) was considerably larger. Decline in scores on the Functional Assessment Questionnaire and Trail Making Test, part B, accounted for approximately 50% of the predictive variance in conversion from mild cognitive impairment to Alzheimer disease. CONCLUSIONS: Cognitive markers at baseline were more robust predictors of conversion than most biomarkers. Longitudinal analyses suggested that conversion appeared to be driven less by changes in the neurobiologic trajectory of the disease than by a sharp decline in functional ability and, to a lesser extent, by declines in executive function.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade
Jack, C. R., Knopman, D. S., Jagust, W. J., Shaw, L. M., Aisen, P. S., Weiner, M. W., Petersen, R. C., & Trojanowski, J. Q. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70299-6 · Cited by 4,806
Alzheimer's Disease Neuroimaging Initiative (ADNI)
Petersen, R. C., Aisen, P. S., Beckett, L. A., Donohue, M. C., Gamst, A. C., Harvey, D. J., Jack, C. R., Jagust, W. J., Shaw, L. M., Toga, A. W., et al. (2010) · Neurology · doi:10.1212/wnl.0b013e3181cb3e25 · Cited by 2,572
Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects
Shaw, L. M., Vanderstichele, H., Knapik‐Czajka, M., Clark, C. M., Aisen, P. S., Petersen, R. C., Blennow, K., Soares, H., Simon, A., Lewczuk, P., et al. (2009) · Annals of Neurology · doi:10.1002/ana.21610 · Cited by 2,065
The role of apolipoprotein E in Alzheimer's disease
Kim, J., Basak, J. M., & Holtzman, D. M. (2009) · Neuron · doi:10.1016/j.neuron.2009.06.026 · Cited by 1,661
Prediction of AD with MRI-based hippocampal volume in mild cognitive impairment
Jack, C. R., Petersen, R. C., Xu, Y. C., O’Brien, P. C., Smith, G. E., Ivnik, R. J., Boeve, B. F., Waring, S. C., Tangalos, E. G., & Kokmen, E. (1999) · Neurology · doi:10.1212/wnl.52.7.1397 · Cited by 1,404
CSF Biomarkers and Incipient Alzheimer Disease in Patients With Mild Cognitive Impairment
Mattsson, N. (2009) · JAMA · doi:10.1001/jama.2009.1064 · Cited by 1,176
Multimodal techniques for diagnosis and prognosis of Alzheimer's disease
Perrin, R. J., Fagan, A. M., & Holtzman, D. M. (2009) · Nature · doi:10.1038/nature08538 · Cited by 702
Comparing predictors of conversion and decline in mild cognitive impairment
Landau, S. M., Harvey, D., Madison, C. M., Reiman, E. M., Foster, N. L., Aisen, P. S., Petersen, R. C., Shaw, L. M., Trojanowski, J. Q., Jack, C. R., et al. (2010) · Neurology · doi:10.1212/wnl.0b013e3181e8e8b8 · Cited by 616
Baseline MRI predictors of conversion from MCI to probable AD in the ADNI cohort
Risacher, S., Saykin, A., Wes, J., Shen, L., Firpi, H., & McDonald, B. (2009) · Current Alzheimer Research · doi:10.2174/156720509788929273 · Cited by 538
Neuropsychological detection and characterization of preclinical Alzheimer’s disease
Jacobs, D. M., Sano, M., Dooneief, G., Marder, K., Bell, K. L., & Stern, Y. (1995) · Neurology · doi:10.1212/wnl.45.5.957 · Cited by 409
Cited by
AD dementia risk in late MCI, in early MCI, and in subjective memory impairment.
Jessen, F., Wolfsgruber, S., Wiese, B., Bickel, H., Mösch, E., Kaduszkiewicz, H., Pentzek, M., Riedel‐Heller, S. G., Luck, T., Fuchs, A., et al. (2014) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2012.09.017 · Cited by 511
Ward, A., Tardiff, S., Dye, C., & Arrighi, H. M. (2013) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000354370 · Cited by 426
Weiner, M. W., Veitch, D. P., Aisen, P. S., Beckett, L. A., Cairns, N. J., Cedarbaum, J., Green, R. C., Harvey, D., Jack, C. R., Jagust, W., et al. (2015) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2014.11.001 · Cited by 348
Cerebral Hemodynamics and Vascular Risk Factors: Setting the Stage for Alzheimer's Disease
de la Torre, J. C. (2012) · Journal of Alzheimer's Disease · doi:10.3233/jad-2012-120793 · Cited by 219
Lombardi, G., Crescioli, G., Cavedo, E., Lucenteforte, E., Casazza, G., Bellatorre, A.-G., Lista, C., Costantino, G., Frisoni, G., Virgili, G., et al. (2020) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009628.pub2 · Cited by 214
When Optimism Hurts: Inflated Predictions in Psychiatric Neuroimaging
Whelan, R., & Garavan, H. (2014) · Biological Psychiatry · doi:10.1016/j.biopsych.2013.05.014 · Cited by 209
APOE2 enhances neuroprotection against Alzheimer’s disease through multiple molecular mechanisms
Conejero-Goldberg, C., Gomar, J. J., Bobes-Bascaran, T., Hyde, T. M., Kleinman, J. E., Herman, M. M., Chen, S., Davies, P., & Goldberg, T. E. (2014) · Molecular Psychiatry · doi:10.1038/mp.2013.194 · Cited by 199
Self-citationPrediction of Conversion to Alzheimer’s Disease with Longitudinal Measures and Time-To-Event Data
Li, K., Chan, W., Doody, R. S., Quinn, J., Luo, S., & Initiative, T. A. D. N. (2017) · Journal of Alzheimer’s Disease · doi:10.3233/jad-161201 · Cited by 126
Alzheimer's disease including focal presentations
Villain, N., & Dubois, B. (2019) · Seminars in Neurology · doi:10.1055/s-0039-1681041 · Cited by 113
Lau, K. M., Parikh, M., Harvey, D. J., Huang, C.-J., & Farias, S. T. (2015) · Journal of the International Neuropsychological Society · doi:10.1017/s1355617715000818 · Cited by 89
The incremental value of neuropsychological assessment: A critical review
Donders, J. (2020) · The Clinical Neuropsychologist · doi:10.1080/13854046.2019.1575471 · Cited by 87
Neuropsychological Features of Mild Cognitive Impairment and Preclinical Alzheimer’s Disease
Salmon, D. P. (2011) · Current Topics in Behavioral Neurosciences · doi:10.1007/7854_2011_171 · Cited by 83
Early neuropsychological detection of Alzheimer's disease
Bastin, C., & Salmon, E. (2014) · European Journal of Clinical Nutrition · doi:10.1038/ejcn.2014.176 · Cited by 72
Damian, M., Hausner, L., Jekel, K., Richter, M., Froelich, L., Almkvist, O., Boada, M., Bullock, R., De Deyn, P. P., Frisoni, G. B., et al. (2013) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000348354 · Cited by 53
Gyebnár, G., Szabó, Á., Sirály, E., Fodor, Z., Sákovics, A., Salacz, P., Hidasi, Z., Csibri, É., Rudas, G., Kozák, L. R., et al. (2018) · Psychiatry Research: Neuroimaging · doi:10.1016/j.pscychresns.2017.10.007 · Cited by 49
Li, K., O'Brien, R., Lutz, M., Luo, S., & Initiative, T. A. D. N. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2017.11.004 · Cited by 44
Weinberger, D. R., & Goldberg, T. E. (2014) · World Psychiatry · doi:10.1002/wps.20096 · Cited by 42
Kiuchi, K., Kitamura, S., Taoka, T., Yasuno, F., Tanimura, M., Matsuoka, K., Ikawa, D., Toritsuka, M., Hashimoto, K., Makinodan, M., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0104007 · Cited by 37
A genetics-based biomarker risk algorithm for predicting risk of Alzheimer's disease
Lutz, M. W., Sundseth, S. S., Burns, D. K., Saunders, A. M., Hayden, K. M., Burke, J. R., Welsh‐Bohmer, K. A., Roses, A. D., & Initiative, A. D. N. (2016) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2015.12.002 · Cited by 30
Bae, S., Harada, K., Lee, S., Harada, K., Makino, K., Chiba, I., Park, H., & Shimada, H. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9051312 · Cited by 29
Wang, Z., Dai, Z., Shu, H., Liu, D., Guo, Q., He, Y., & Zhang, Z. (2017) · Journal of Alzheimer’s Disease · doi:10.3233/jad-160724 · Cited by 26
Anti-Correlated Cerebrospinal Fluid Biomarker Trajectories in Preclinical Alzheimer’s Disease
Gomar, J. J., Conejero-Goldberg, C., Davies, P., Goldberg, T. E., & Initiative, F. T. A. D. N. (2016) · Journal of Alzheimer’s Disease · doi:10.3233/jad-150937 · Cited by 13
Self-citation
Metadata
- Authors
- Gomar, J. J.
- Venue
- Archives of General Psychiatry
- Publisher
- American Medical Association (AMA)
- Published
- 2011-09-01
- Volume
- 68
- Issue
- 9
- Pages
- 961
- ISSN
- 0003-990X (ISSN-L)
- OpenAlex
- W1976817527
- Cited by
- 340
- References
- 11
- FWCI
- 18.32
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.